For this purpose, in the current study, we investigated the anti-inflammatory potential of an AHR agonist produced by the gut microbiota, tryptamine, in the limiting of autoimmune neuroinflammation in experimental MS. This evidence concerns the gene AHR and myeloid sarcoma.